Literature DB >> 28857548

Effect of BN Nanoparticles Loaded with Doxorubicin on Tumor Cells with Multiple Drug Resistance.

Irina Y Zhitnyak1, Igor N Bychkov1, Irina V Sukhorukova2, Andrey M Kovalskii2, Konstantin L Firestein2,3, Dmitri Golberg3,4, Natalya A Gloushankova1, Dmitry V Shtansky2.   

Abstract

Herein we study the effect of doxorubicin-loaded BN nanoparticles (DOX-BNNPs) on cell lines that differ in the multidrug resistance (MDR), namely KB-3-1 and MDR KB-8-5 cervical carcinoma lines, and K562 and MDR i-S9 leukemia lines. We aim at revealing the possible differences in the cytotoxic effect of free DOX and DOX-BNNP nanoconjugates on these types of cells. The spectrophotometric measurements have demonstrated that the maximum amount of DOX in the DOX-BNNPs is obtained after saturation in alkaline solution (pH 8.4), indicating the high efficiency of BNNPs saturation with DOX. DOX release from DOX-BNNPs is a pH-dependent and DOX is more effectively released in acid medium (pH 4.0-5.0). Confocal laser scanning microscopy has shown that the DOX-BNNPs are internalized by neoplastic cells using endocytic pathway and distributed in cell cytoplasm near the nucleus. The cytotoxic studies have demonstrated a higher sensitivity of the leukemia lines to DOX-BNNPs compared with the carcinoma lines: IC50(DOX-BNNPs) is 1.13, 4.68, 0.025, and 0.14 μg/mL for the KB-3-1, MDR KB-8-5, K562, and MDR i-S9 cell lines, respectively. To uncover the mechanism of cytotoxic effect of nanocarriers on MDR cells, DOX distribution in both the nucleus and cytoplasm has been studied. The results indicate that the DOX-BNNP nanoconjugates significantly change the dynamics of DOX accumulation in the nuclei of both KB-3-1 and KB-8-5 cells. Unlike free DOX, the utilization of DOX-BNNPs nanoconjugates allows for maintaining a high and stable level of DOX in the nucleus of MDR KB-8-5 cells.

Entities:  

Keywords:  DOX-BNNP nanoconjugates; carcinoma and leukemia cell lines; cytotoxic effect; drug loading; multidrug resistant tumor cells

Mesh:

Substances:

Year:  2017        PMID: 28857548     DOI: 10.1021/acsami.7b08713

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  5 in total

1.  Efficacy of Surface-Modified PLGA Nanoparticles as a Function of Cervical Cancer Type.

Authors:  Lee B Sims; Keegan C Curry; Sindhu Parupalli; Gwynneth Horner; Hermann B Frieboes; Jill M Steinbach-Rankins
Journal:  Pharm Res       Date:  2019-03-13       Impact factor: 4.200

2.  Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance.

Authors:  Federica Bessone; Chiara Dianzani; Monica Argenziano; Luigi Cangemi; Rita Spagnolo; Federica Maione; Enrico Giraudo; Roberta Cavalli
Journal:  Cancer Drug Resist       Date:  2021-03-19

3.  Plasma Surface Polymerized and Biomarker Conjugated Boron Nitride Nanoparticles for Cancer-Specific Therapy: Experimental and Theoretical Study.

Authors:  Elizaveta S Permyakova; Liubov Yu Antipina; Philipp V Kiryukhantsev-Korneev; Andrey M Kovalskii; Josef Polčak; Anton Manakhov; Kristina Yu Gudz; Pavel B Sorokin; Dmitry V Shtansky
Journal:  Nanomaterials (Basel)       Date:  2019-11-21       Impact factor: 5.076

4.  Homotypic targeting and drug delivery in glioblastoma cells through cell membrane-coated boron nitride nanotubes.

Authors:  Daniele De Pasquale; Attilio Marino; Christos Tapeinos; Carlotta Pucci; Silvia Rocchiccioli; Elena Michelucci; Francesco Finamore; Liam McDonnell; Alice Scarpellini; Simone Lauciello; Mirko Prato; Aitor Larrañaga; Filippo Drago; Gianni Ciofani
Journal:  Mater Des       Date:  2020-04-23       Impact factor: 7.991

5.  In Vivo and In Vitro Anticancer Activity of Doxorubicin-loaded DNA-AuNP Nanocarrier for the Ovarian Cancer Treatment.

Authors:  Chang-Seuk Lee; Tae Wan Kim; Da Eun Oh; Su Ok Bae; Jaesung Ryu; Hyejeong Kong; Hyeji Jeon; Hee Kyung Seo; Seob Jeon; Tae Hyun Kim
Journal:  Cancers (Basel)       Date:  2020-03-09       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.